G protein-coupled receptors (GPCRs), the largest family of targets for approved drugs, are rarely targeted for malignancy treatment, except for certain endocrine and hormone-responsive tumors. results from public malignancy gene expression databases confirm the expression of such GPCRs. We propose that highly expressed GPCRs in malignancy cells (for Asunaprevir inhibition example, GPRC5A in PDAC and… Continue reading G protein-coupled receptors (GPCRs), the largest family of targets for approved